Compare BHP Billiton Limited (BHP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs ResMed Inc. — how do they compare? BHP Billiton Limited trades at $90.24 (market cap $229.15B), while ResMed Inc. trades at $224.92 (market cap $32.61B). The key difference: BHP Billiton Limited is far larger — about 7× ResMed Inc.'s market cap, and BHP Billiton Limited pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BHP | RMD | |
|---|---|---|
Market Cap | $229.15B | $32.61B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $293.73 |
52-Week Low | $52.14 | $182.82 |
Enterprise Value | $243.35B | $31.97B |
Dividend Yield | 2.95% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.36, down 0.28% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q4 2025 earnings, missing EPS estimates, while Q2 2025 beat expectations. Revenue for 2024 was $55.66B with a net income margin of 18.97%, though profitability has fluctuated in recent years. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production and revenue streams.
Outlook is cautious due to operational risks from strikes and volatile commodity prices, but strong cash flow and institutional buying support long-term value. Analysts are predominantly neutral with 65% hold ratings, reflecting balanced risk-reward. Key risks include labor disputes and copper output misses, while opportunities lie in AI-driven copper demand growth and cost management.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
